Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020

Talla, Cheikh; Loucoubar, Cheikh; Roka, Jerlie Loko; Barry, Mamadou Aliou; Ndiaye, Seynabou; Diarra, Maryam; Thiam, Mareme Seye; Faye, Oumar; Dia, Moussa; Diop, Mamadou; Ndiaye, Oumar; Tall, Adama; Faye, Rokhaya; Mbow, Adji Astou; Diouf, Babacar; Diallo, Jean Pierre; Keita, Ibrahima Mamby; Ndiaye, Mamadou; Woudenberg, Tom; White, Michael T.; Jim, Ting; Diagne, Cheikh Tidiane; Pasi, Omer; Diop, Boly; Sall, Amadou Alpha; Vigan-Womas, Inès; Faye, Ousmane

doi:10.1016/j.ijregi.2022.02.007

Cited by 20 publications

(12 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results show that men are twice more likely to die from COVID-19, but also advanced age (over 65 years old) and the presence of comorbidities such as diabetes and hypertension and cardiovascular diseases are associated factors for COVID-19 death. This is was not surprising and is consistent with what has been observed not only in Africa [14,[17][18][19][20][21][22] but in other countries of the world [23][24][25][26]. Indeed, studies conducted in Spain by Pastor-Barriuso and colleagues [25] showed that older men are more exposed to coronavirus mortality.…”

Section: Plos Onesupporting

confidence: 86%

“…This study, based on surveillance data, confirms the trends in the spatial distribution of COVID-19 observed cases in the national seroprevalence survey. Indeed, the most affected regions described in our study were confirmed by the seroprevalence survey [22] with the exception of the Thies region. In fact, the IPD laboratory had data from the Thies region for only the 2 first months of the pandemic.…”

Section: Plos Onesupporting

confidence: 81%

“…A slow growth rate (0.031 per day, 95%CI = 0.028-0.034) of the epidemic in Senegal was observed, with a similar rate for Dakar (0.033 per day, 95%CI = 0.03-0.037). As of October 31, 2020, the doubling time of the epidemic in Senegal was 22 days (95%CI = 20-25 days), 20 days (19)(20)(21)(22)(23) in Dakar (S5 Table ).…”

Section: Plos Onementioning

confidence: 99%

See 2 more Smart Citations

First wave COVID-19 pandemic in Senegal: Epidemiological and clinical characteristics

Diarra

Barry²,

Dia³

et al. 2022

PLoS ONE

Self Cite

View full text Add to dashboard Cite

Background The novel coronavirus disease 2019 (COVID-19) pandemic has spread from China to the rest of the world. Africa seems less impacted with lower number of cases and deaths than other continents. Senegal recorded its first case on March 2, 2020. We present here data collected from March 2 to October 31, 2020 in Senegal. Methods Socio-demographic, epidemiological, clinical and virological information were collected on suspected cases. To determine factors associated with diagnosed infection, symptomatic disease and death, multivariable binary logistic regression and log binomial models were used. Epidemiological parameters such as the reproduction number and growth rate were estimated. Results 67,608 suspected cases were tested by the IPD laboratories (13,031 positive and 54,577 negative). All age categories were associated with SARS-CoV-2 infection, but also patients having diabetes or hypertension or other cardiovascular diseases. With diagnosed infection, patients over 65 years and those with hypertension and cardiovascular disease and diabetes were highly associated with death. Patients with co-morbidities were associated with symptomatic disease, but only the under 15 years were not associated with. Among infected, 27.67% were asymptomatic (40.9% when contacts were systematically tested; 12.11% when only symptomatic or high-risk contacts were tested). Less than 15 years-old were mostly asymptomatic (63.2%). Dakar accounted for 81.4% of confirmed cases. The estimated mean serial interval was 5.57 (± 5.14) days. The average reproduction number was estimated at 1.161 (95%CI: 1.159–1.162), the growth rate was 0.031 (95%CI: 0.028–0.034) per day. Conclusions Our findings indicated that factors associated with symptomatic COVID-19 and death are advanced age (over 65 years-old) and comorbidities such as diabetes and hypertension and cardiovascular disease.

show abstract

Section: Plos Onesupporting

confidence: 86%

Section: Plos Onesupporting

confidence: 81%

See 1 more Smart Citation

First wave COVID-19 pandemic in Senegal: Epidemiological and clinical characteristics

Diarra

Barry²,

Dia³

et al. 2022

PLoS ONE

Self Cite

View full text Add to dashboard Cite

show abstract

“…The high SARS-CoV-2 total RBD antibodies' prevalence described in our study is comparable to that reported from other West African countries at similar times. In Senegal, national SARS-CoV-2 seroprevalence was 28.1% in October-November 2020, at the end of their first transmission wave [28], similar to the prevalence in Farafenni at the same time. Furthermore, in Togo, nationwide seroprevalence in May-June 2021 was 64.3%, which is similar to the prevalence in Farafenni after the second wave [29].…”

Section: Sars-cov-2 Sero-prevalence Increased Significantly Among Pre...mentioning

confidence: 55%

SARS-CoV-2 seroprevalence in pregnant women during the first three COVID-19 waves in The Gambia

Janha,

Bah,

Jah

et al. 2023

Preprint

View full text Add to dashboard Cite

Objectives SARS-CoV-2 transmission in Sub-Saharan Africa has probably been underestimated. Population-based seroprevalence studies are needed to determine the extent of transmission in the continent. Methods Blood samples from a cohort of Gambian pregnant women were tested for SARS-CoV-2 total IgM/IgG before (Pre-pandemic1: October-December 2019 and Pre-pandemic2: February-June 2020) and during the pandemic (Post-wave1: October-December 2020, Post-wave2: May-June 2021; and Post-wave3: October-December 2021). Samples positive for total SARS-CoV-2 IgM/IgG were tested for protein-specific antibodies. Results SARS-CoV-2 total IgM/IgG seroprevalence was 0.9% 95%CI (0.2, 4.9) in Pre-pandemic1; 4.1% (1.4, 11.4) in Pre-pandemic2; 31.1% (25.2, 37.7) in Post-wave1; 62.5% (55.8, 68.8) in Post-wave2 and 90.0% (85.1, 93.5) in Post-wave3. S-protein IgG and NCP-protein IgG seroprevalence also increased at each Post-wave period. Although S-protein IgG and NCP-protein IgG seroprevalence was similar at Post-wave1, S-protein IgG seroprevalence was higher at Post-wave2 and Post-wave3, [prevalence difference (PD) 13.5 (0.1, 26.8) and prevalence ratio (PR) 1.5 (1.0, 2.3) in Post-wave2; and 22.9 (9.2, 36.6) and 1.4 (1.1, 1.8) in Post-wave3 respectively, p<0.001]. Conclusion SARS-CoV-2 transmission in The Gambia during the first three COVID-19 waves was high, differing significantly from official numbers of COVID-19 cases reported. Our findings are important for policy makers in managing the near-endemic COVID-19.

show abstract

“…They found that the overall positivity rate was 20.4% and significant geographical differences in seropositivity with a higher seroprevalence in Dakar, around 40% [38]. Then, Talla et al found an adjusted national prevalence of anti-SARS-CoV-2 IgG/IgM in Senegal estimated to be 28.4% between October 24 and November 26, 2020 [39]. A high SARS-CoV-2 seroprevalences and its variability between localities were also reported in the second national population based cross-sectional survey (72,2%) conducted in November 2021 [40] and among pregnant women attending the antenatal consultation (69,4%) during the second and third waves of COVID-19 in Senegal [41].…”

Section: Discussionmentioning

confidence: 99%

Serological Survey in a university community after the fourth wave of COVID-19 in Senegal

Thiam,

Diouara,

Ndiaye

et al. 2024

Preprint

Self Cite

View full text Add to dashboard Cite

Cross-sectional survey was conducted to assess the true extent of COVID-19 exposure among students and staff of Polytechnic High School (PHS). Random cluster sampling was carried out between May 19 and August 18, 2022, after the fourth wave of COVID-19 transmission. IgM and IgG SARS-CoV-2 antibodies were screened using WANTAI SARS-CoV-2 ELISA assays. Seroprevalence and descriptive statistics were calculated. Moreover, the associations between seropositivity and different factors (age, gender, preventive, etc.) were determined using logistic regression. A total of 637 participants were recruited, including 563 students, followed by 52 TAS officers, and 22 professors. The median age among was 21 years [18 - 63]. 62.0% of the participants were female, and 36.89% were male, with a male-to-female ratio = 0.59. The overall IgG and IgM seroprevalence were 92% and 6.91% respectively. We found a higher IgM seroprevalence in men than women (9.4% vs. 5.6%) and a lower IgM seroprevalence in (18-25) age group compared to (55-65) years. Low compliance with preventive measures was found with a significant IgM seroprevalence depending on non-respect of social distancing (p = 0.008). IgM seropositivity was associated with Body Mass Indice (BMI) categorized (O.R. 0.238, p = 0.043), ethnic group (O.R. 0.723, p = 0.046) and marital status (O.R. 2.399, p = 0.021). Moreover, IgG seropositivity was associated with vaccination status (O.R. 4.741, p < 0.001). Our study revealed that the majority of students and staff have already been exposed to SARS-CoV-2, which confirms the circulation of SARS-CoV-2 in PHS at the time of the survey. Our results underline the importance of seroepidemiological surveys to estimate the real impact of the COVID-19 pandemic in a community and to monitor disparities in antibody response in the population.

show abstract

Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020

Cited by 20 publications

References 22 publications

First wave COVID-19 pandemic in Senegal: Epidemiological and clinical characteristics

First wave COVID-19 pandemic in Senegal: Epidemiological and clinical characteristics

SARS-CoV-2 seroprevalence in pregnant women during the first three COVID-19 waves in The Gambia

Serological Survey in a university community after the fourth wave of COVID-19 in Senegal

Contact Info

Product

Resources

About